Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma
Research output: Contribution to journal › Journal article › Research › peer-review
In a time of increasing treatment options for multiple myeloma bone disease, risk factors predicting progression need to be elucidated. This study investigated the value of serum YKL-40, previously shown to be associated with radiographic progression of bone destruction, as a predictor for time to clinical progression, i.e. skeletal-related events (SREs), in 230 newly diagnosed patients with multiple myeloma receiving intravenous bisphosphonates. Serum concentrations of YKL-40 and biochemical bone markers (CTX-MMP, CTX-I, PINP) were measured at diagnosis. Patients were evaluated every third month for SRE and at 9 and 24 months for radiographic progression. Elevated serum YKL-40 was seen in 47% of patients and associated with high-risk disease (International Staging System stage III; p < 0.001), increased bone resorption (serum CTX/MMP; p < 0.001) and early radiographic progression at 9 months (p = 0.01). Serum YKL-40 together with serum CTX-MMP/PINP ratio and World Health Organization status were independent predictors of time to first SRE.
Original language | English |
---|---|
Journal | Leukemia and Lymphoma |
Volume | 56 |
Issue number | 9 |
Pages (from-to) | 2650-9 |
Number of pages | 10 |
ISSN | 1042-8194 |
DOIs | |
Publication status | Published - 2015 |
ID: 162114766